<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01119898</url>
  </required_header>
  <id_info>
    <org_study_id>COV05100031</org_study_id>
    <nct_id>NCT01119898</nct_id>
  </id_info>
  <brief_title>Exploratory Study of PENNSAID Gel to Treat Symptoms of Knee Osteoarthritis</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Clinical Study to Evaluate the Safety and Efficacy of PENNSAID Gel in the Symptomatic Treatment of Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteoarthritis (OA) is the most common form of arthritis. It can cause pain, swelling, and
      reduced motion in the joints. That can reduce quality of life.

      OA can occur in any joint, but usually affects the hands, knees, hips or spine.

      The purpose of this study is to find out if doctors might be able to use 2% PENNSAID gel to
      treat OA in the knee.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2, 2010</start_date>
  <completion_date type="Actual">February 16, 2011</completion_date>
  <primary_completion_date type="Actual">February 16, 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain When Walking On A Flat Surface</measure>
    <time_frame>at Baseline</time_frame>
    <description>Participants rate their pain intensity when walking on a flat surface as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain When Walking On A Flat Surface</measure>
    <time_frame>at Week 4</time_frame>
    <description>Participants rate their pain intensity when walking on a flat surface as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain When Going Up Or Down Stairs</measure>
    <time_frame>at Baseline</time_frame>
    <description>Participants rate their pain intensity when going up or down stairs as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain When Going Up Or Down Stairs</measure>
    <time_frame>at Week 4</time_frame>
    <description>Participants rate their pain intensity when going up or down stairs as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain At Night While In Bed</measure>
    <time_frame>at Baseline</time_frame>
    <description>Participants rate their pain intensity at night while in bed as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain At Night While In Bed</measure>
    <time_frame>at Week 4</time_frame>
    <description>Participants rate their pain intensity at night while in bed as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain While Sitting Or Lying Down</measure>
    <time_frame>at Baseline</time_frame>
    <description>Participants rate their pain intensity while sitting or lying down as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain While Sitting Or Lying Down</measure>
    <time_frame>at Week 4</time_frame>
    <description>Participants rate their pain intensity while sitting or lying down as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain While Standing</measure>
    <time_frame>at Baseline</time_frame>
    <description>Participants rate their pain intensity while standing as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain While Standing</measure>
    <time_frame>at Week 4</time_frame>
    <description>Participants rate their pain intensity while standing as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>PENNSAID Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diclofenac sodium 2.0% w/w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The complete carrier containing ingredients at the same concentrations as experimental arm without diclofenac sodium</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PENNSAID Gel</intervention_name>
    <description>2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks</description>
    <arm_group_label>PENNSAID Gel</arm_group_label>
    <other_name>diclofenac sodium 2.0% w/w</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Primary osteoarthritis of the knee

          2. Radiologic evidence of OA of the knee

          3. On stable pain therapy with an oral or topical NSAID or acetaminophen

          4. Experience a &quot;moderate flare&quot; of pain following washout of stable pain therapy

          5. Able to read and understand English or Spanish to answer pain assessment questions
             without any explanation

          6. If female, surgically sterile or non-pregnant

          7. Except for OA, in reasonably good general health

          8. Written informed consent

        Exclusion Criteria:

          1. Secondary OA of the study knee

          2. History of pseudo gout or inflammatory flare-ups

          3. Participation would conflict with contraindications, warnings or precautions as stated
             in the prescribing information for oral or topical diclofenac

          4. Severe, uncontrolled cardiac, renal, hepatic, or other systemic disease

          5. Any malignancy within the previous 3 years, except local therapy for superficial skin
             cancer not on the study knee

          6. Known sensitivity to the use of oral or topical diclofenac, aspirin [acetylsalicylic
             acid (ASA)] or any other NSAID, dimethyl sulfoxide (DMSO), or ethanol

          7. Ongoing abnormality that could confound interpretation of the safety results (eg,
             anemia, unresponsive gastrointestinal [GI] reflux, etc.)

          8. Documented gastroduodenal ulcer or any GI bleeding (except hemorrhoidal) within the
             last 6 months

          9. Uncontrolled diabetes

         10. Screening laboratory test results of serum creatinine ≥ 1.5 times upper limit of
             normal; aspartate aminotransferase (AST), alanine aminotransferase (ALT), or
             gamma-glutamyltransferase (GGT) ≥ 3 times upper limit of normal; and hemoglobin less
             than or equal to lower limit of normal

         11. Documented alcohol or drug abuse within 1 year

         12. If female, breast-feeding

         13. Major surgery or previous damage to the study knee at any time, or minor knee surgery
             to the study knee within 1 year

         14. Requires oral or intra-muscular corticosteroids, or received an intra articular
             corticosteroid injection into the study knee within the past 90 days, or into any
             other joint within the past 30 days, or currently applying topical corticosteroids
             onto the study knee

         15. Received intra-articular viscosupplementation (eg, hylan G-F 20 [Synvisc®]) in the
             study knee in the past 6 months

         16. On prior stable therapy (ie, more than 3 days per week for the previous month) with an
             opioid analgesic prior to the screening visit will be excluded.

         17. Recently started taking a sedative hypnotic medication for insomnia

         18. Taking anti-depressants

         19. Not willing to discontinue prohibited medications/therapies

         20. Cannot tolerate acetaminophen

         21. Re-entering study after dropping out or withdrawn from study

         22. Used another investigational drug within the previous 30 days

         23. On or currently applying for disability benefits on the basis of knee OA

         24. History of fibromyalgia

         25. Other painful or disabling conditions affecting the knee or leg, or disabling
             condition of the hands (used to apply the study drug)

         26. Skin disorder with current involvement on the hands (used to apply the study drug) or
             the knee(s) (application site)

         27. Referred to an orthopedic surgeon for consideration of, or been advised to have, knee
             replacement or knee reconstruction surgery

         28. Radiologic evidence of OA of the knee advanced to the point that all cartilage has
             been eroded (ie, bone on bone)

         29. Recently started using a cane within the past 30 days

         30. History of chronic headaches that may require more than occasional use of rescue
             medication for headaches
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Pierro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mallinckrodt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Genova Clinical Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Bay Medical Research, Inc</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive NeuroScience Inc.</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33716</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drug Studies America</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Coast Medical Group</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Technology, Inc.</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research</name>
      <address>
        <city>Erlanger</city>
        <state>Kentucky</state>
        <zip>41018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Inc.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sundance Clinical Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Center of Asheville</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peters Medical Research, LLC</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crescent Medical Research</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Hanover Medical Research</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Source, Inc.</name>
      <address>
        <city>Perrysburg</city>
        <state>Ohio</state>
        <zip>43551</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Inc.</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Medical Research</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group Clinical Research</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Research Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HypotheTest, LLC</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 28, 2010</study_first_submitted>
  <study_first_submitted_qc>May 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2010</study_first_posted>
  <results_first_submitted>May 17, 2017</results_first_submitted>
  <results_first_submitted_qc>October 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2019</results_first_posted>
  <last_update_submitted>October 18, 2019</last_update_submitted>
  <last_update_submitted_qc>October 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Arthritis</keyword>
  <keyword>NSAIDs</keyword>
  <keyword>Topical NSAID</keyword>
  <keyword>Diclofenac</keyword>
  <keyword>PENNSAID</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One person who failed screening was randomized in error, but did not receive study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PENNSAID Gel</title>
          <description>Diclofenac sodium 2.0% w/w</description>
        </group>
        <group group_id="P2">
          <title>Vehicle</title>
          <description>The complete carrier containing ingredients at the same concentrations as experimental arm without diclofenac sodium</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug (mITT)</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
                <participants group_id="P2" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
                <participants group_id="P2" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medical procedure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized in error did not participate</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Modified Intent-to-Treat (mITT) - all participants who were randomized and received study drug</population>
      <group_list>
        <group group_id="B1">
          <title>PENNSAID Gel</title>
          <description>Diclofenac sodium 2.0% w/w</description>
        </group>
        <group group_id="B2">
          <title>Vehicle</title>
          <description>The complete carrier containing ingredients at the same concentrations as experimental arm without diclofenac sodium</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="130"/>
            <count group_id="B2" value="129"/>
            <count group_id="B3" value="259"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.2" spread="9.23"/>
                    <measurement group_id="B2" value="61.9" spread="9.07"/>
                    <measurement group_id="B3" value="61.1" spread="9.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="174"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain When Walking On A Flat Surface</title>
        <description>Participants rate their pain intensity when walking on a flat surface as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
        <time_frame>at Baseline</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>PENNSAID Gel</title>
            <description>Diclofenac sodium 2.0% w/w
PENNSAID Gel: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>The complete carrier containing ingredients at the same concentrations as experimental arm without diclofenac sodium
Vehicle: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pain When Walking On A Flat Surface</title>
          <description>Participants rate their pain intensity when walking on a flat surface as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
          <population>mITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extreme</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain When Walking On A Flat Surface</title>
        <description>Participants rate their pain intensity when walking on a flat surface as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
        <time_frame>at Week 4</time_frame>
        <population>mITT population with non-missing data at Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>PENNSAID Gel</title>
            <description>Diclofenac sodium 2.0% w/w
PENNSAID Gel: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>The complete carrier containing ingredients at the same concentrations as experimental arm without diclofenac sodium
Vehicle: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pain When Walking On A Flat Surface</title>
          <description>Participants rate their pain intensity when walking on a flat surface as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
          <population>mITT population with non-missing data at Week 4</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extreme</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain When Going Up Or Down Stairs</title>
        <description>Participants rate their pain intensity when going up or down stairs as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
        <time_frame>at Baseline</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>PENNSAID Gel</title>
            <description>Diclofenac sodium 2.0% w/w
PENNSAID Gel: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>The complete carrier containing ingredients at the same concentrations as experimental arm without diclofenac sodium
Vehicle: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pain When Going Up Or Down Stairs</title>
          <description>Participants rate their pain intensity when going up or down stairs as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
          <population>mITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extreme</title>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain When Going Up Or Down Stairs</title>
        <description>Participants rate their pain intensity when going up or down stairs as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
        <time_frame>at Week 4</time_frame>
        <population>mITT population with non-missing data at Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>PENNSAID Gel</title>
            <description>Diclofenac sodium 2.0% w/w
PENNSAID Gel: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>The complete carrier containing ingredients at the same concentrations as experimental arm without diclofenac sodium
Vehicle: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pain When Going Up Or Down Stairs</title>
          <description>Participants rate their pain intensity when going up or down stairs as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
          <population>mITT population with non-missing data at Week 4</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extreme</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain At Night While In Bed</title>
        <description>Participants rate their pain intensity at night while in bed as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
        <time_frame>at Baseline</time_frame>
        <population>mITT population with non-missing data at Baseline</population>
        <group_list>
          <group group_id="O1">
            <title>PENNSAID Gel</title>
            <description>Diclofenac sodium 2.0% w/w
PENNSAID Gel: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>The complete carrier containing ingredients at the same concentrations as experimental arm without diclofenac sodium
Vehicle: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pain At Night While In Bed</title>
          <description>Participants rate their pain intensity at night while in bed as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
          <population>mITT population with non-missing data at Baseline</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extreme</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain At Night While In Bed</title>
        <description>Participants rate their pain intensity at night while in bed as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
        <time_frame>at Week 4</time_frame>
        <population>mITT population with non-missing data at Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>PENNSAID Gel</title>
            <description>Diclofenac sodium 2.0% w/w
PENNSAID Gel: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>The complete carrier containing ingredients at the same concentrations as experimental arm without diclofenac sodium
Vehicle: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pain At Night While In Bed</title>
          <description>Participants rate their pain intensity at night while in bed as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
          <population>mITT population with non-missing data at Week 4</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extreme</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain While Sitting Or Lying Down</title>
        <description>Participants rate their pain intensity while sitting or lying down as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
        <time_frame>at Baseline</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>PENNSAID Gel</title>
            <description>Diclofenac sodium 2.0% w/w
PENNSAID Gel: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>The complete carrier containing ingredients at the same concentrations as experimental arm without diclofenac sodium
Vehicle: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pain While Sitting Or Lying Down</title>
          <description>Participants rate their pain intensity while sitting or lying down as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
          <population>mITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extreme</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain While Sitting Or Lying Down</title>
        <description>Participants rate their pain intensity while sitting or lying down as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
        <time_frame>at Week 4</time_frame>
        <population>mITT population with non-missing data at Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>PENNSAID Gel</title>
            <description>Diclofenac sodium 2.0% w/w
PENNSAID Gel: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>The complete carrier containing ingredients at the same concentrations as experimental arm without diclofenac sodium
Vehicle: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pain While Sitting Or Lying Down</title>
          <description>Participants rate their pain intensity while sitting or lying down as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
          <population>mITT population with non-missing data at Week 4</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extreme</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain While Standing</title>
        <description>Participants rate their pain intensity while standing as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
        <time_frame>at Baseline</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>PENNSAID Gel</title>
            <description>Diclofenac sodium 2.0% w/w
PENNSAID Gel: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>The complete carrier containing ingredients at the same concentrations as experimental arm without diclofenac sodium
Vehicle: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pain While Standing</title>
          <description>Participants rate their pain intensity while standing as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
          <population>mITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extreme</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain While Standing</title>
        <description>Participants rate their pain intensity while standing as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
        <time_frame>at Week 4</time_frame>
        <population>mITT population with non-missing data at Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>PENNSAID Gel</title>
            <description>Diclofenac sodium 2.0% w/w
PENNSAID Gel: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>The complete carrier containing ingredients at the same concentrations as experimental arm without diclofenac sodium
Vehicle: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pain While Standing</title>
          <description>Participants rate their pain intensity while standing as none, mild, moderate, severe or extreme. The number of participants who rate their pain in each category is presented.</description>
          <population>mITT population with non-missing data at Week 4</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extreme</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Participants were only counted once for each body system/preferred term.</desc>
      <group_list>
        <group group_id="E1">
          <title>PENNSAID Gel</title>
          <description>Diclofenac sodium 2.0% w/w</description>
        </group>
        <group group_id="E2">
          <title>Vehicle</title>
          <description>The complete carrier containing ingredients at the same concentrations as experimental arm without diclofenac sodium</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site dryness</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Application site exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Application site pruritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information Call Center</name_or_title>
      <organization>Mallinckrodt Pharmaceuticals</organization>
      <phone>800-556-3314</phone>
      <email>clinicaltrials@mnk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

